Data / Form D filings / GT Biopharma, Inc.
GT Biopharma, Inc.: Form D filings
GT Biopharma, Inc., a biotechnology company in San Francisco, CA, filed 12 Form D notices with the SEC between 2014 and 2026. The latest, on September 29, 2026, reports $7.8 million sold of a $39 million offering to 9 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 505 MONTGOMERY STREET 10TH FLOOR, San Francisco, CA, 94111
- Phone
- (415) 919-4040
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 109657
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Sep 29, 2026 | New notice | $38,958,054 | $7,750,000 | $31,208,054 | 9 | Sep 14, 2026 | sec.gov |
| May 28, 2025 | New notice | $20,000,000 | $0 | $20,000,000 | 2 | May 14, 2025 | sec.gov |
| May 27, 2025 | New notice | $5,950,000 | $5,950,000 | 9 | May 12, 2025 | sec.gov | |
| Mar 7, 2025 | New notice | $1,280,358 | $1,280,358 | 6 | Feb 25, 2025 | sec.gov | |
| Jul 23, 2020 | Amendment | Indefinite | $5,607,000 | 18 | Apr 20, 2020 | sec.gov | |
| Jun 12, 2020 | New notice | Indefinite | $2,417,000 | 9 | Apr 20, 2020 | sec.gov | |
| Aug 17, 2018 | New notice | $5,140,000 | $5,140,000 | 13 | Aug 2, 2018 | sec.gov | |
| Feb 6, 2018 | New notice | $7,055,000 | $7,055,000 | 14 | Jan 23, 2018 | sec.gov | |
| Sep 14, 2017 | New notice | $4,540,000 | $4,540,000 | 9 | Aug 31, 2016 | sec.gov | |
| Jul 27, 2015 | New notice | $1,500,000 | $500,000 | $1,000,000 | 2 | Jul 9, 2015 | sec.gov |
| Mar 16, 2015 | New notice | $3,000,000 | $2,050,000 | $950,000 | 7 | Feb 20, 2015 | sec.gov |
| Jul 31, 2014 | New notice | $1,425,000 | $1,425,000 | 11 | Jul 24, 2014 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Michael Breen | Executive Officer, Director | Chief Executive Officer |
| Alan Urban | Executive Officer | Chief Financial Officer |
| Charles J. Casamento | Director | |
| Hilary Kramer | Director | |
| David C. Mun-Gavin | Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Sep 28, 2026 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what GT Biopharma, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.